Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPB-51602 dose-escalation in relapsed/refractory hematologic malignancies
jRCT2080221439Phase 1
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Apr 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of opb-51602 in multiple myeloma (MM), non-Hodgkin lymphoma (NHL), acute myeloid leukemia (AML) and 2 more, sponsored by Otsuka Pharmaceutical Co., Ltd.
02
Drugs
opb-51602
03
Conditions
multiple myeloma (MM)non-Hodgkin lymphoma (NHL)acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on jRCT2080221439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221439.